Labcorp and Waters partner for cervical cancer screening access
Labcorp will offer the BD Onclarity HPV Assay by year-end, expanding access to HPV testing and cervical cancer screening through self-collected specimens.
By Chanelle Malambo/peopleimages.com on Adobe Stock (601827138)
6adf5c4783e5b78ef57a7859 Adobestock 601827138
Labcorp will offer the BD Onclarity HPV Assay at its facilities by the end of this year through a new partnership with Waters Corporation.
The BD Onclarity HPV Assay is compatible with self-collected specimens and allows for extended genotyping of high-risk HPV types 16, 18, 31, 45, 51, and 52.
The goal of this action is to make cervical cancer screening more accessible. The companies hope to ensure more women receive timely HPV testing by making the assay available through Labcorp’s clinician programs, Gaps in Care health plan programs, and consumer channels.
